Office of the Director, National Institutes of Health; Notice of Meeting, 58965 [E9-27485]

Agencies

• DEPARTMENT OF HEALTH AND HUMAN SERVICES
• National Institutes of Health

[Federal Register Volume 74, Number 219 (Monday, November 16, 2009)]
[Notices]
[Page 58965]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-27485]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: December 1-2, 2009.
    Time: December 1, 2009, 9 a.m. to 5:30 p.m.; December 2, 2009, 
8:30 a.m. to 4:15 p.m.
    Agenda: The Recombinant DNA Advisory Committee will review and 
discuss selected human gene transfer protocols as well as related 
data management activities. Protocols to be reviewed include a 
protocol for Leber congenital amaurosis using an AAV vector, a 
protocol for adenosine deaminase severe combined immunodeficiency 
disease (ADA SCID) using a lentiviral vector and a protocol for 
alpha 1 antitrypsin deficiency using an AAV vector. Additional 
discussions include an update on a trial that used a lentiviral 
vector for beta-thalassemia and sickle cell disease and a discussion 
of proposed final changes to the NIH Guidelines for Research 
Involving Recombinant DNA to address synthetic nucleic acids. 
Finally, an experiment involving the introduction of tetracycline 
resistance into non-ocular strains of Chlamydia trachomatis will be 
discussed as required under Section III-A-1 of the NIH Guidelines 
for Research Involving Recombinant DNA Molecules. Further 
information on this research can be found in the October 28, 2009 
Federal Register (74 FR 55568). An agenda for the meeting will be 
available on the OBA Web site (https://oba.od.nih.gov/rdna_rac/rac_meetings.html).
    Place: National Institutes of Health, Natcher Building, 45 
Center Drive, Bethesda, MD 20892.
    Contact Person: Laurie Lewallen, Advisory Committee Coordinator, 
Office of Biotechnology Activities, National Institutes of Health, 
6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985, 301-496-
9839, Lewallenl@od.nih.gov.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: https://oba.od.nih.gov/rdna/rdna.html, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: November 9, 2009.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-27485 Filed 11-13-09; 8:45 am]
BILLING CODE 4140-01-P